From Boom to Gloom: SPAC Frenzy Fizzles in Asia after US Falters
The SPAC bandwagon that rolled out of the U.S. has gone off the rails in Asia. Some listed SPACs have been liquidated, and the volume of SPAC applications in Singapore…
Viva Biotech Dispenses Bitter Pill of Slowing Growth, Asset Devaluation
The contract drug services provider lost roughly 100 million yuan in the first half of this year, as its revenue growth underperformed its peers Key Takeaways: Viva Biotech’s eked out…
RELATED ARTICLES
-
Seyond may get stuck in slow-moving SPAC lane to Hong Kong listing
7855.HK -
ZG Group set to forge Hong Kong’s second De-SPAC listing
2572.HK
- An Apple Anti-Trust Probe, and Hong Kong’s Second SPAC Merger
- Hong Kong gains clout as preferred IPO watering hole for Chinese companies
- Youlife chases SPAC listing after death of Hong Kong IPO
- A Shifting IPO Tide, and China Stocks Get Cold Shoulder in Europe
